MPOXED

Mpox recovery is proving far less straightforward than once assumed. Findings published in Annals of Internal Medicine show that more than half of patients continued to experience physical or functional sequelae up to 18 months after acute infection. Persistent scarring and ongoing anorectal or urinary dysfunction were common, even when psychosocial symptoms resembled those of at-risk but uninfected individuals. These data reinforce that mpox is not always a short-lived illness. Long-term follow-up and integrated care should be considered routine components of mpox management, not exceptional measures.

Africa’s decision to lift mpox as a Public Health Emergency of Continental Security reflects a hard-earned shift from crisis response to sustained control. Under the leadership of Africa CDC, coordinated action, regional solidarity, and international partnership drove sharp declines in cases and fatalities while expanding surveillance, laboratory capacity, vaccination, and research. This milestone should not be misread as closure. Mpox remains endemic in parts of the continent, and the transition now demands vigilance, investment, and country-led ownership to consolidate gains and prevent resurgence.

Mpox has been widely framed as an acute illness, but new evidence challenges that narrative. Research published in Annals of Internal Medicine shows that for many patients, recovery does not end when lesions heal. Persistent scarring, functional complications, and social consequences including stigma and job loss continue long after infection. As clade IIb mpox circulates at low levels and clade I resurges elsewhere, public health responses must expand beyond containment. Long-term follow-up, rehabilitation, and psychosocial support should be treated as integral components of mpox care, not afterthoughts.

New research suggests mpox is both quieter and more persistent than surveillance systems assume. Evidence published in Nature Communications points to silent circulation in Nigeria, where immune markers reveal recent mpox exposure without recognized illness. At the same time, findings in Annals of Internal Medicine show that more than half of patients experience lasting physical or psychosocial effects long after diagnosis. Together, these studies challenge symptom-based surveillance and short-term care models. Mpox control must account for unseen transmission and long-term consequences, not just reported cases.

Mpox continues to be framed as a short-lived illness, but growing evidence suggests otherwise. Findings published in Annals of Internal Medicine show that more than half of patients experienced persistent physical, functional, or psychosocial effects more than a year after clade II infection. Scarring, anorectal and urinary symptoms, depression, and social disruption were common even after clinically mild disease. These data challenge assumptions that recovery ends with lesion resolution and point to the need for longer-term clinical follow-up and supportive care for people recovering from mpox.

Thailand’s mpox response shows what sustained, risk-informed public health action looks like after headlines fade. By pairing surveillance with targeted outreach, the Department of Disease Control has acknowledged the epidemiologic reality that close contact, including sexual contact, is driving transmission. Strategic vaccine allocation to high-risk areas and populations reflects pragmatic prevention, not stigma. Continued public education, early care-seeking, and transparent guidance from the Ministry of Public Health are essential to keep localized outbreaks from becoming entrenched, especially in tourism-heavy regions.

New findings reported in The Lancet Infectious Diseases complicate assumptions about mpox immunity. Among smallpox-naive adults, prior mpox infection produced stronger and more durable immune memory than vaccination with the MVA-BN vaccine. As breakthrough infections increase, these data suggest population-level immunity may erode faster than anticipated. While vaccination remains essential for prevention, especially during outbreaks, the results underscore the need to reassess durability, booster strategies, and how natural infection data should inform long-term mpox control planning.

Mexico’s first confirmed mpox case caused by clade Ib is a reminder that viral evolution and global mobility remain tightly linked. While there is no evidence of community transmission, the detection of a more virulent clade previously concentrated in Africa underscores the importance of vigilant surveillance beyond endemic regions. The World Health Organization and national health authorities are right to emphasize monitoring, rapid case identification, and vaccination readiness. Imported cases may be clinically manageable in high-resource settings, but their appearance signals that mpox remains a global concern that demands sustained attention, not episodic alarm.

Mpox has faded from headlines, but it has not faded from reality. With sustained transmission in Africa, emerging recombinant strains, and sporadic imported cases elsewhere, the virus continues to evolve under the radar. Evidence summarized in Nature underscores how clade diversity, sexual transmission dynamics, and viral persistence complicate control efforts. The appearance of a recombinant strain and unanswered questions about fertility impacts should sharpen global attention. Surveillance, vaccination of at-risk populations, and continued research are not precautionary luxuries. They are the minimum requirements to prevent mpox from re-emerging as a broader and more adaptive global threat.